Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaratumab plus doxorubicin versus placebo plus doxorubicin in advanced or metastatic soft tissue sarcoma
NL-OMON47908Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2015
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in soft tissue sarcoma (STS) and leiomyosarcoma (LMS) comparing Olaratumab plus doxorubicin with Placebo plus doxorubicin (2 arms). Primary endpoint: Overall survival. Started Dec 2015; status: active, not recruiting.
02
Drugs
olaratumabdoxorubicin
03
Conditions
soft tissue sarcoma (STS)leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NL-OMON47908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47908.